Treatment of myelogenous leukemia: current status and investigational options

Blood. 1996 Apr 15;87(8):3069-81.

Authors

H M Kantarjian¹, S O'Brien, P Anderlini, M Talpaz

Affiliation

¹ Department of Hematology, M.D. Anderson Cancer Center Houston TX, 77030, USA.

PMID: 8605319

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Bone Marrow Transplantation
Cytarabine / therapeutic use
Harringtonines / therapeutic use
Hematopoietic Stem Cell Transplantation
Homoharringtonine
Humans
Immunologic Factors / therapeutic use
Interferon-alpha / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Prognosis
Randomized Controlled Trials as Topic
Remission Induction
Risk Factors
Salvage Therapy
Treatment Outcome

Substances

Antineoplastic Agents
Harringtonines
Immunologic Factors
Interferon-alpha
Cytarabine
Homoharringtonine

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.

Alternative Proxies:

Alternative Proxy